ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 978

Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis

Gerd Horneff1, Ivan Foeldvari2, Ralf Trauzeddel3, Toni Hospach4, Kirsten Minden5, Hans-Iko Huppertz6,7 and Ariane Klein8, 1Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, 2Hamburger Zentrum fur, Kinder-und Jugendrheumatologie, Hamburg, Germany, 3Helios Clinics, Berlin, Germany, 4Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, 5Charité–Universitätsmedizin Berlin, Berlin, Germany, 6Prof Hess Clinic, Bremen, Germany, 7Prof. Hess Childrens Hospital, Bremen, Germany, 8Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologic drugs, Juvenile arthritis and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S115 ACR/ARHP Abstract: Pediatric Rheum (976–981)

Session Type: ACR/ARHP Combined Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most prevalent chronic diseases of childhood and adolescence. Evidence suggests that early effective treatment is important to minimize the burden of disease during childhood and in further life. We hypothesize that a guided treat to target (T2T) approach as recommended by the German Society for Pediatric Rheumatology (1) is superior to routine care in polyarticular JIA (pJIA) in terms of reaching a clinical state of remission after 12 months of treatment.

Methods: After informed consent, patients with early (disease duration ≤ 12 months) and active (JADAS10 ≥ 5.4) pJIA were enrolled. Targets for treatment were defined by the level of improvement and are progressively more rigourous with ongoing treatment. Failure to meet a defined target required modification of treatment at specified intervals. Initially, all patients received methotrexate(MTX). The choice of biologic was made by shared decision between the investigator and the patient/parent and not influenced by the protocol. Minimal treatment target defined as recognizable improvement of disease activity (2) was demanded after 3 months of treatment. Until month 6, a JADAS acceptable disease status, until month 9 JADAS MDA and at month 12 JADAS-remission should be reached.

Results: Altogether 58 patient with non-systemic JIA (44/7 RF negative/RF positive polyarthritis, 3 extended Oligoarthritis, 1 ERA, 1PsA)were included (mean age 9.2+/-4.9 years, disease duration 0.4+/-0.6 years). At month 3; 37/51 (72.5%) of patients showed JADAS improvement. In 13 (25.5%) treatment with a biologic was started. At month 6, 32/41 (78%) had JADAS improvement and 30/41 (73.2%) reached JADAS acceptable disease. In 6 (14.6%) a biologic agent was started. At month 9, 34/37 (92%) showed JADAS improvement, 28/37 (76%) reached JADAS acceptable disease and 23/37 (62%) reached JADAS-MDA. In 4 (10.8%) a biologic was started and one patient switched biologics. So far, 30 patients completed 12 months of observation. JADAS MDA was reached by 22 (76%) and JADAS remission was reached by 13 (45%). In total 24 patients were treated with a biologic agent, 12 (41%) of those were followed until month 12 with 3 patients (25%) reaching JADAS remission and 7 (58%) JADAS MDA. 17 patients were treated with MTX only over 12 months of whom 10 (59%) reached JADAS remission and 15 (88%) JADAS MDA.

N

Baseline n=58

Month 3 n=51

Month 6 n=41

Month 9 n=37

Month 12 n=30

JADAS- minimal response

n.a.

72,5%

78,0%

91,9%

96.5%

JADAS acceptable disease (≤5.4)

0,0%

43,1%

73,2%

75,7%

79.3%

JADAS MDA (≤3.8)

0,0%

33,3%

61,0%

62,2%

75.8%

JADAS Remission (≤1)

0,0%

19,6%

31,7%

43,2%

44.8%

NSAIDs

41,4%

25,5%

12,2%

5,4%

0,0%

Steroids

36,2%

31,4%

12,2%

5,4%

3,3%

MTX

100,0%

88,2%

100,0%

83,8%

76,7%

Biologics

0,0%

25,5%

36,6%

40,5%

41.4%

2nd biologic

0,0%

0,0%

0,0%

2,7%

3,3%

Conclusion: These preliminary data indicate that a T2T concept is feasible. A high rate of patients reached JADAS MDA and JADAS remission after 12 months of treatment. Interestingly, about 60% of patients did not need to be treated with a biologic to reach predefined T2T (2). Thus, the early response seems advantageous indicating a window of opportunity to successfully treat polyarticular JIA.

1. Horneff G et al Pediatr Rheumatol Online J. 2017; 15:78

2. Horneff G et Becker I. Rheumatology. 2014;53:1229-34.


Disclosure: G. Horneff, None; I. Foeldvari, None; R. Trauzeddel, None; T. Hospach, None; K. Minden, None; H. I. Huppertz, None; A. Klein, None.

To cite this abstract in AMA style:

Horneff G, Foeldvari I, Trauzeddel R, Hospach T, Minden K, Huppertz HI, Klein A. Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/treat-to-target-study-for-improved-outcome-in-polyarticular-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treat-to-target-study-for-improved-outcome-in-polyarticular-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology